Shares of ImmunityBio, Inc. (NASDAQ: IBRX) jumped roughly 7.5% after the Emirates Drug Establishment (EDE) granted Marketing Authorization for ANKTIVA® (nogapendekin alfa inbakicept) across two…
July 29, 2026
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ: CAPR) announced that The Lancet has published results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel, the company’s investigational cell therapy…
Forte Biosciences (FBRX) shares rocketed higher Monday after the company agreed to sell itself to Belgian-Dutch immunology specialist argenx (ARGX) in a deal valued at…
July 24, 2026
MannKind Stock Jumps 5.7% as FDA Clears Furoscix ReadyFlow™ and Company Locks In $50M Placement
MannKind Corporation (MNKD) opened the morning with momentum, as its shares climbed 5.7% in premarket trading. Investors reacted quickly to two announcements that landed together:…
Medpace Holdings (MEDP) shares surged roughly 18% Wednesday after the contract research organization blew past Wall Street’s second-quarter estimates and posted a sharp rebound in…
July 21, 2026
Tempest and Senlang Join Forces to Advance TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Tempest Therapeutics (Nasdaq: TPST) announced today that it has entered a strategic partnership with Hebei Senlang Biotechnology Co., Ltd. to develop TPST-4003, its lead in…
July 20, 2026
Tempus AI to Acquire Personalis in $1.5B Deal — Needham Flags a Premium Well Above Peers
Tempus AI, Inc. (NASDAQ: TEM) has agreed to buy cancer-test maker Personalis, Inc. (NASDAQ: PSNL) in a $1.5 billion deal that Needham says carries a…
July 20, 2026
Oncolytics Biotech® Wins FDA Fast Track Designation for Pelareorep in Later-Stage Anal Cancer
Oncolytics Biotech Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to…
Nuvectis Pharma (NASDAQ: NVCT) has reinvented itself almost overnight. Once known primarily for a single mid-stage oncology drug, the company vaulted into the rare-disease arena…
Vera Therapeutics, Inc. (NASDAQ: VERA), a biotechnology company focused on serious immunological diseases, saw shares rise 6% on July 6, 2026 as investors positioned ahead…
Novartis (NYSE: NVS / SIX: NOVN.SW) is moving deeper into next-generation cancer treatment. The Swiss pharma giant announced Monday it will acquire UK biotech Myricx…
July 01, 2026
FDA Approves Orca Bio’s Tregzi, Ushering In a First-of-Its-Kind Cell Therapy for Transplant Patients
The FDA has cleared Orca Bio’s allogeneic T cell–based immunotherapy, Tregzi, to reduce graft-versus-host disease (GVHD) in patients undergoing treatment for blood cancers. Notably, Orca…